Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
EUCR was delisted on the 26th of April, 2023.
31 hedge funds and large institutions have $47.8M invested in Eucrates Biomedical Acquisition Corp. Ordinary Shares in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.
500% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 2
48% more funds holding
Funds holding: 21 → 31 (+10)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
14% more capital invested
Capital invested by funds: $41.8M → $47.8M (+$6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$3.94M |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$1.97M |
| 3 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$1.65M |
| 4 |
D.E. Shaw & Co
New York
|
+$1.19M |
| 5 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
+$984K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Shay Capital
New York
|
-$3.7M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$984K |
| 3 |
CAC
Cowen and Company
New York
|
-$652K |
| 4 |
CC
Centiva Capital
New York
|
-$3.94K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.52K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Goldman Sachs
New York
| $109K | +$109K | +11,099 | New |
|
|
EAM
27
Exos Asset Management
New York
| $103K | – | – | – |
|
|
PAM
28
Panagora Asset Management
Boston,
Massachusetts
| $98K | +$97.7K | +9,922 | New |
|
29
Morgan Stanley
New York
| $38K | +$38.4K | +3,900 | New |
|
|
30
UBS Group
Zurich,
Switzerland
| $37K | -$1.52K | -155 | -4% |
|
|
MF
31
Magnetar Financial
Evanston,
Illinois
| $116 | +$116K | +11,800 | New |
|
|
CAC
32
Cowen and Company
New York
| – | -$652K | -65,296 | Closed |
|
EUCR Hedge Fund Activity: Q2 2021 in Review
31 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) for Q2 2021, worth a combined $47.8M — up 14% from $41.8M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new EUCR positions and 2 closed out — a net gain of 10 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Altium Capital Management, opening a new position worth an estimated $3.94M. The largest seller was Shay Capital, cutting an estimated $3.7M.
- 31 institutional investors held Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) as of Q2 2021, up from 21 in Q1 2021.
- Funds reported $47.8M of Eucrates Biomedical Acquisition Corp. Ordinary Shares stock for Q2 2021, up 14% quarter-over-quarter.
- 12 funds opened new Eucrates Biomedical Acquisition Corp. Ordinary Shares positions in Q2 2021 and 2 closed out, a net change of +10 holders.
- The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares buyer in Q2 2021 was Altium Capital Management, an estimated $3.94M added.
- The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares seller in Q2 2021 was Shay Capital, an estimated $3.7M sold.
Based on aggregated 13F filings for Q2 2021.